Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly versus insulin detemir in type 2 diabetes
2009-010830-23Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly with Insulin detemir once or twice daily (2 arms). Primary endpoint: Composite glycemic and weight endpoint at study endpoint. Started Jul 2009; status: completed.
02
Drugs
exenatideinsulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-010830-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010830-23.